Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 5;29(22):5234.
doi: 10.3390/molecules29225234.

Nucleoside Analogues for Chagas Disease and Leishmaniasis Therapy: Current Status and Future Perspectives

Emmanuel Awucha Nwoke  1 , Silvester Lowe  1 , Fawaz Aldabbagh  1 , Karunakaran Kalesh  2 , Hachemi Kadri  1
Affiliations
Review

Nucleoside Analogues for Chagas Disease and Leishmaniasis Therapy: Current Status and Future Perspectives

Emmanuel Awucha Nwoke et al. Molecules. .

Abstract

Chagas disease and leishmaniasis are two neglected tropical diseases that affect millions of people in low- and middle-income tropical countries. These diseases caused by protozoan parasites pose significant global health challenges, which have been exacerbated by the recent COVID-19 pandemic. There is an urgent need for novel therapeutics as current treatments are limited by toxicity and drug resistance. Nucleoside analogues, which have been extensively studied and successfully applied in antiviral and antitumor therapies, hold potential that has yet to be fully explored for treating these neglected diseases. In this review, we discuss the use of nucleoside analogues as promising therapeutic agents for Chagas disease and leishmaniasis. After briefly examining the pathology, progression, and current treatment options for these diseases, we provide a comprehensive analysis of the status of nucleoside analogues and explore their prospects. By outlining the current landscape and future directions, this review aims to guide research and development efforts towards more effective nucleoside-based treatments for Chagas disease and leishmaniasis.

Keywords: Leishmania; NTDs; T. cruzi; Trypanosoma; nucleoside analogues; purine; pyrimidine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Current treatments for Chagas disease and leishmaniasis.
Figure 2
Figure 2
Nucleoside analogues with anti-Chagas disease activity.
Figure 3
Figure 3
Nucleoside analogues with anti-leishmanial activity.
Figure 4
Figure 4
Mechanism of action of allopurinol in Leishmania and T. cruzi.
See this image and copyright information in PMC

References

    1. Malecela M.N., Ducker C. A road map for neglected tropical diseases 2021–2030. Trans. R. Soc. Trop. Med. Hyg. 2021;115:121–123. doi: 10.1093/trstmh/trab002. - DOI - PMC - PubMed
    1. Swaminathan S., Pécoul B., Abdullah H., Christou C., Gray G., IJsselmuiden C., Kieny M.P., Mazzucato M., von Messling V., Ogutu B., et al. Reboot biomedical R&D in the global public interest. Nature. 2022;602:207–210. doi: 10.1038/d41586-022-00324-y. - DOI - PubMed
    1. Adam T., Ralaidovy A.H., Ross A.L., Reeder J.C., Swaminathan S. Tracking global resources and capacity for health research: Time to reassess strategies and investment decisions. Health Res. Policy Syst. 2023;21:93. doi: 10.1186/s12961-023-00979-7. - DOI - PMC - PubMed
    1. Molyneux D.H., Aboe A., Isiyaku S., Bush S. COVID-19 and neglected tropical diseases in Africa: Impacts, interactions, consequences. Int. Health. 2020;12:367–372. doi: 10.1093/inthealth/ihaa040. - DOI - PMC - PubMed
    1. Santos S.S., De Araújo R.V., Giarolla J., Seoud O.E., Ferreira E.I. Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: A review. Int. J. Antimicrob. Agents. 2020;55:105906. doi: 10.1016/j.ijantimicag.2020.105906. - DOI - PubMed

LinkOut - more resources